|Brand Name:||Alfasin XR|
|Type:||Tablet (Extended Release)|
|Therapeutic Class:||Alpha adrenoceptor blocking drugs|
|Manufacturer:||Incepta Pharmaceuticals Limited|
|Last Updated:||2020-11-21 18:15:00|
Alfasin XR Tablet (Extended Release) contains Alfuzosin Hydrochloride. Alfasin XR uses:
Alfuzosin Hydrochloride is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia(BPH), lower urinary tract symptoms (LUTS) including urinary frequency, nocturia, incomplete emptying and urinary hesitancy associated with BPH.
Alfasin XR Tablet (Extended Release) contains Alfuzosin Hydrochloride 10 mg. Alfasin XR doses:
The recommended dosage is one 10 mg Alfuzosin Hydrochloride tablet daily to be taken immediately after the same meal each day. The tablets should not be chewed or crushed.
Alfuzosin Hydrochloride tablet should be swallowed whole.
This formulation is generally well tolerated. However the following adverse events have been reported include abdominal pain, dyspepsia, constipation, nausea, impotence, bronchitis, sinusitis and pharyngitis.
Alfuzosin Hydrochloride is a selective antagonist of post-synaptic a1 adrenoreceptors, which are located in the prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra. Alfuzosin Hydrochloride relaxes the tone of the prostate smooth muscle, prostate capsule, bladder neck and proximal urethra. It competitively and selectively binds to the post synaptic a1-adrenergic receptors in the lower urinary tract. It also relaxes sympathetic nervous stimulation, reduces resting urethral pressure and inhibits urethral hypertonia-induced sympathetic nervous stimulation. As an uroselective agent, Alfuzosin Hydrochloride preferentially binds to prostatic a1 receptors, blockage of these receptors result in reduction of BPH symptoms, improvement of urine flow and decreased potential for hypertensive events.
Alfuzosin Hydrochloride should not be given to patients with moderate or severe hepatic insufficiency. Caution should be exercised when Alfuzosin is administered in patients with severe renal insufficiency. If symptoms of angina pectoris should newly appear or worsen, Alfuzosin Hydrochloride should be discontinued.
Alfuzosin may interact with other alpha-blockers, Atenolol, Cimetidine, Diltiazem, Ketoconazole and Ritonavir.
Alfuzosin Hydrochloride is not indicated for use in pregnant and lactating mother.
Alfuzosin Hydrochloride tablet is contraindicated for hypersensitivity to Alfuzosin Hydrochloride, history of orthostatic hypotension, combination with other alpha-1 receptor blockers, hepatic insufficiency.
Efficacy of Alfuzosin Hydrochloride has not been demonstrated in children aged 2 to 16 years. Therefore Alfuzosin Hydrochloride is not indicated for use in the paediatric population.
Overdose of Alfuzosin Hydrochloride should lead to hypotension; support of the cardiovascular system is of first importance. Restoration of blood pressure and normalization of heart rate may be accomplished by keeping the patient in the supine position. If this measure is inadequate, then the administration of intravenous fluids should be considered. If necessary, vasopressors should then be used, and the renal function should be monitored and supported as needed.
Store in a cool and dry place, protected from light
Alfasin XR Tablet (Extended Release) price in Bangladesh 14.00